title: Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma.
abstract: OBJECTIVE
  To compare oncologic outcomes in an international cohort of patients who underwent either partial ureterectomy (PU) or radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).
  
  
  METHODS
  A subgroup of patients from the UTUC Collaboration with operation classified as PU or RNU was used (n = 835). Clinicopathologic outcomes were evaluated. Survival was assessed using the Kaplan-Meier method. Cox regression addressed recurrence-free survival (RFS) and cancer-specific survival (CSS).
  
  
  RESULTS
  Median age and follow-up were 69 years (range 32-97 years) and 34 months (range 1-246 months), respectively. Relapse occurred in 28.5% of patients (19.6% local, 8.9% systemic). At analysis, 180 patients (21.6%) died of UTUC. Eighty-one patients (9.7%) underwent PU and 754 (90.3%) underwent RNU. High tumor grade (77.3% vs 55.6%, P <.001) and advanced T stage (>T1, 41.7% vs 30.9%, P <.001) were significantly more common in the RNU cohort. Significantly more patients in the PU group received adjuvant chemotherapy than the RNU arm (25.9% vs 16.8%, respectively, P = .05). Kaplan-Meier median 5-year survival probabilities for RFS (69.4% vs 75.9%, P = .06) and CSS (67.5% vs 72.1%, P = .06) were not significantly different between PU and RNU. On multivariable analysis, Eastern Cooperative Oncology Group (ECOG) performance status, tumor stage, tumor necrosis, and lymph node (LN) status were significantly associated with CSS.
  
  
  CONCLUSIONS
  In patients with UTUC, PU seems to provide oncologic efficacy equal to RNU. Ability to maximize global renal function with utilization of PU is an attractive strategy in carefully selected patients.
authors.affiliation: Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA.
authors.forename: Aditya
authors.initials: A
authors.lastname: Bagrodia
authors.forename: Franklin E
authors.initials: FE
authors.lastname: Kuehhas
authors.forename: Bishoy A
authors.initials: BA
authors.lastname: Gayed
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Wood
authors.forename: Jay D
authors.initials: JD
authors.lastname: Raman
authors.forename: Payal
authors.initials: P
authors.lastname: Kapur
authors.forename: Ithaar H
authors.initials: IH
authors.lastname: Derweesh
authors.forename: Karim
authors.initials: K
authors.lastname: Bensalah
authors.forename: Arthur I
authors.initials: AI
authors.lastname: Sagalowsky
authors.forename: Shahrokh F
authors.initials: SF
authors.lastname: Shariat
authors.forename: Yair
authors.initials: Y
authors.lastname: Lotan
authors.forename: Vitaly
authors.initials: V
authors.lastname: Margulis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009392:Nephrectomy / Q000379:methods*; D011379:Prognosis; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology; D014513:Ureter / Q000473:pathology / Q000601:surgery*; D014516:Ureteral Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D019459:Urothelium / Q000473:pathology*